Portada›Martes 23 de diciembre de 2025
Biomédicas del NASDAQ ante la SEC, martes 23 de diciembre de 2025
Los 48 documentos que 39 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.
← lunes 22 de diciembre de 2025 · lunes 29 de diciembre de 2025 →
El día, bloque a bloque
Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.
Emisiones y dilución
- BCTXBriaCell Therapeutics Corp.S-1Capacidad de emisión registradaEDGAR
En el documentoContrasplit de accionestexto original ▸
…compliance with the minimum bid price requirement. Under the Nasdaq Excessive Reverse Stock Split Rule, if a company’s common shares fail to meet the minimum bid price requirement and the company has effected a reverse stock split within the prior one-year period, it will not be eligible for any compliance period to address a bid price deficiency. Accordingly, if our common shares fall out of compliance with the minimum bid requirement…
- CVKDCadrenal Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
- FBLGFibroBiologics, Inc.S-1Capacidad de emisión registradaEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…Withum Smith+Brown, PC, an independent registered public accounting firm, as stated in their report incorporated by reference herein (which report includes an explanatory paragraph about the existence of substantial doubt concerning the Company’s ability to continue as a going concern). Such audited financial statements are incorporated herein by reference in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. WHERE YOU CAN FIND ADDITIONAL…
- MBRXMoleculin Biotech, Inc.424B5Nueva emisión de acciones con precioEDGAR
En el documentoPrograma de venta continua de acciones (ATM)texto original ▸
Filed Pursuant to Rule 424(b)(5) Registration No. 333-280064 Prospectus Supplement No. 1 (to Prospectus dated July 1, 2024) Moleculin Biotech, Inc. Up to $8,200,000 Common Stock We have previously entered into an At The Market Offering Agreement (“ATM Agreement”) with Roth Capital Partners, LLC (“Roth”) relating to shares of our common stock offered by this prospectus supplement and the prospectus dated July 11, 2025 (the “July 2025…
- MBRXMoleculin Biotech, Inc.S-3Capacidad de emisión registradaEDGAR
En el documentoContrasplit de accionestexto original ▸
…date as determined by the board of directors in its sole discretion prior to the one-year anniversary of the annual meeting. Pursuant to such authority granted by our stockholders, our board of directors approved a one-for-twenty-five (1:25) reverse stock split (the “Reverse Stock Split”) of our common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with the Secretary of State of the State of Delaware and…
- NTHINEONC TECHNOLOGIES HOLDINGS, INC.424B5Nueva emisión de acciones con precioEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…report of our independent registered public accounting firm on our financial statements as of and for the year ended December 31, 2024 and 2023 included an explanatory paragraph indicating that there was substantial doubt about our ability to continue as a going concern. See Note 1 to our annual financial statements appearing at the end of this prospectus for additional information on our assessment. In December 2022, the Company signed a Letter of Intent (“LOI”) with…
- ONCOOnconetix, Inc.424B3Prospecto suplementario o de reventaEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…assurance that additional capital will be available to us on acceptable terms, or at all, or that we will ever generate revenue sufficient to provide self-sustaining cash flows. These circumstances raise substantial doubt about our ability to continue as a going concern. The condensed consolidated financial statements incorporated by reference in this prospectus do not include any adjustment that might be necessary if the Company is unable to continue as a going concern…
En el documentoContrasplit de accionestexto original ▸
…in this prospectus do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. 2 Recent Developments Reverse Stock Split On June 13, 2025, the Company effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-eighty-five (1:85). The Company accounted for the reverse stock split on a retrospective basis pursuant to Accounting Standards…
- RADXRadiopharm Theranostics Ltd424B5Nueva emisión de acciones con precioEDGAR
- VRCAVerrica Pharmaceuticals Inc.424B3Prospecto suplementario o de reventaEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…2024 financial statements contains an explanatory paragraph that states that the Company has incurred substantial operating losses since inception and has negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of that uncertainty. WHERE YOU CAN FIND ADDITIONAL INFORMATION This prospectus is part of the registration statement…
- KZIAKAZIA THERAPEUTICS LTD424B3Prospecto suplementario o de reventaEDGAR
- KZIAKAZIA THERAPEUTICS LTD424B3Prospecto suplementario o de reventaEDGAR
- KZIAKAZIA THERAPEUTICS LTD424B3Prospecto suplementario o de reventaEDGAR
- KZIAKAZIA THERAPEUTICS LTD424B3Prospecto suplementario o de reventaEDGAR
- NERVMinerva Neurosciences, Inc.S-3Capacidad de emisión registradaEDGAR
- RADXRadiopharm Theranostics Ltd424B3Prospecto suplementario o de reventaEDGAR
Participaciones y control
- CAMPCamp4 Therapeutics CorpSC 13D/ACambio en participación significativaEDGAR
- INDVIndivior Pharmaceuticals, Inc.SC 13D/ACambio en participación significativaEDGAR
- LONALeonaBio, Inc.SC 13D/ACambio en participación significativaEDGAR
- RXRXRECURSION PHARMACEUTICALS, INC.SC 13D/ACambio en participación significativaEDGAR
- TRIBTRINITY BIOTECH PLCSC 13D/ACambio en participación significativaEDGAR
- VORVor Biopharma Inc.SC 13DCambio en participación significativaEDGAR
Informes y hechos relevantes
- ALLRAllarity Therapeutics, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
- CAMPCamp4 Therapeutics Corp8-KFin de acuerdo materialEDGAR
- CELUCelularity Inc8-KVenta de acciones no registrada (colocación privada)EDGAR
- INDPIndaptus Therapeutics, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
En el documentoCambio en la dirección de la empresatexto original ▸
…was appointed as Chairperson of the Company’s Nominating Committee filling the vacancy of Ms. Karah. Appointment of Co-Chief Executive Officer In accordance with the Purchase Agreement, the Board also appointed David Lazar as the Co-Chief Executive Officer of the Company, effective at Closing. David E. Lazar (35) David Lazar currently serves as the CEO and Chairman of Kala Bio Inc. (NASDAQ: KALA) since December, 2025. David previously served as Chief Executive…
- JUNSJUPITER NEUROSCIENCES, INC.8-KVenta de acciones no registrada (colocación privada)EDGAR
- RNAZTranscode Therapeutics, Inc.8-K/AOtros hechos relevantesEDGAR
- CNTBConnect Biopharma Holdings Ltd8-KCambio en el consejo o la direcciónEDGAR
- CTORCITIUS ONCOLOGY, INC.10-KInforme anualEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…addition, such statements could be affected by risks and uncertainties related to: ● our independent registered public accounting firm’s report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern; ● our need for substantial additional funds and its ability to raise those funds; ● our ongoing evaluation of strategic alternatives; ● our ability to successfully commercialize LYMPHIR, including covering…
- CTORCITIUS ONCOLOGY, INC.8-KResultadosEDGAR
- CTXRCitius Pharmaceuticals, Inc.10-KInforme anualEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…addition, such statements could be affected by risks and uncertainties related to: ● our independent registered public accounting firm’s report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern; ● our need for substantial additional funds and its ability to raise those funds; ● our ongoing evaluation of strategic alternatives; ● the ability of Citius Oncology to commercialize LYMPHIR, including…
En el documentoContrasplit de accionestexto original ▸
…Company was not in compliance with the Bid Price Rule and, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company was not eligible for any compliance period due to the fact that the Company had effected a reverse stock split during the prior one-year period. The Company timely requested an appeal of Nasdaq’s determination, which stayed the suspension and delisting of the Company’s common stock pending a the Panel’s decision…
- CTXRCitius Pharmaceuticals, Inc.8-KResultadosEDGAR
- CVKDCadrenal Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
- DYNDyne Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
- FLNAFILANA THERAPEUTICS, INC.8-KNuevo acuerdo materialEDGAR
- FTHFaeth Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
- GNPXGenprex, Inc.8-KOtros hechos relevantesEDGAR
- HINDVyome Holdings, Inc8-KNuevo acuerdo materialEDGAR
- INMBInmune Bio, Inc.8-KNuevo acuerdo materialEDGAR
- IRWDIRONWOOD PHARMACEUTICALS INC8-KNuevo acuerdo materialEDGAR
- IVVDInvivyd, Inc.8-KOtros hechos relevantesEDGAR
En el documentoDesignación de vía rápida (Fast Track)texto original ▸
…Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID NEW HAVEN, Conn., Dec. 23, 2025 – Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational vaccine-alternative monoclonal antibody candidate for the prevention of COVID. Fast Track is a process that enables the FDA to expedite the development and review of new…
- KRYSKrystal Biotech, Inc.8-KCambio en el consejo o la direcciónEDGAR
- MBIOMUSTANG BIO, INC.8-KOtros hechos relevantesEDGAR
- NMADNOMAD POWER SOLUTIONS, INC.8-KNuevo acuerdo materialEDGAR
- ONMDOneMedNet Corp8-KOtros hechos relevantesEDGAR
- PHIOPhio Pharmaceuticals Corp.8-KOtros hechos relevantesEDGAR
- SKYESkye Bioscience, Inc.8-KNuevo acuerdo materialEDGAR
- TCRTAlaunos Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
← lunes 22 de diciembre de 2025 · lunes 29 de diciembre de 2025 →
Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.
Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.